Cargando…
HYDAMTIQ, a selective PARP‐1 inhibitor, improves bleomycin‐induced lung fibrosis by dampening the TGF‐β/SMAD signalling pathway
Idiopathic pulmonary fibrosis is a severe disease characterized by excessive myofibroblast proliferation, extracellular matrix and fibrils deposition, remodelling of lung parenchyma and pulmonary insufficiency. Drugs able to reduce disease progression are available, but therapeutic results are unsat...
Autores principales: | Lucarini, Laura, Durante, Mariaconcetta, Lanzi, Cecilia, Pini, Alessandro, Boccalini, Giulia, Calosi, Laura, Moroni, Flavio, Masini, Emanuela, Mannaioni, Guido |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264150/ https://www.ncbi.nlm.nih.gov/pubmed/27704718 http://dx.doi.org/10.1111/jcmm.12967 |
Ejemplares similares
-
Effects of PARP-1 Deficiency and Histamine H(4) Receptor Inhibition in an Inflammatory Model of Lung Fibrosis in Mice
por: Durante, Mariaconcetta, et al.
Publicado: (2019) -
Poly(ADP-ribose) polymerase inhibition with HYDAMTIQ reduces allergen-induced asthma-like reaction, bronchial hyper-reactivity and airway remodelling
por: Lucarini, Laura, et al.
Publicado: (2014) -
The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways
por: Mini, Enrico, et al.
Publicado: (2017) -
Role of Histamine H(3) Receptor Antagonists on Intraocular Pressure Reduction in Rabbit Models of Transient Ocular Hypertension and Glaucoma
por: Lanzi, Cecilia, et al.
Publicado: (2019) -
Effects of New NSAID-CAI Hybrid Compounds in Inflammation and Lung Fibrosis
por: Lucarini, Laura, et al.
Publicado: (2020)